Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.

American journal of obstetrics and gynecology - 1 Apr 2018

Patel Shreeya, Legood Rosa, Evans D Gareth, Turnbull Clare, Antoniou Antonis C, Menon Usha, Jacobs Ian, Manchanda Ranjit

Abstract excerpt

BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effective compared with family history based testing in Ashkenazi Jewish women. However, only 1 of the 3 Ashkenazi Jewish BRCA1/BRCA2 founder mutations (185delAG[c.68_69delAG]), 5382insC[c.5266dupC]), and 6174delT[c.5946delT]) is found in the Sephardi Jewish population (185delAG[c.68_69delAG]), and the overall...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Hereditary Breast and Ovarian Cancer Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hormone Replacement Therapy

Share to Life Expectancy

Share to Mammography

Share to Ovariectomy

Share to Prophylactic Mastectomy

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 29288066
DOI: 10.1016/j.ajog.2017.12.221

Genes

BRCA1
BRCA2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.PMID 29288066Read ↗

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.Semantic proximity Read ↗

Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.Semantic proximity Read ↗

Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.Semantic proximity Read ↗

Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population.Semantic proximity Read ↗

A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testingSemantic proximity Read ↗

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.Semantic proximity Read ↗

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.Semantic proximity Read ↗

Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence.Semantic proximity Read ↗

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.Semantic proximity Read ↗

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.Semantic proximity Read ↗

Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.Semantic proximity Read ↗

An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.